Skip to content
‹ Back to IndustriesHealthcare

GAINING REGULATORY APPROVAL

In reviewing medical devices, the FDA cares primarily about two things: Safety and Efficacy In order for a company to market a medical device in the United States, it is necessary that they gain approval from the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Ensuring FDA approval requires evidence that…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In reviewing medical devices, the FDA cares primarily about two things: Safety and Efficacy

In order for a company to market a medical device in the United States, it is necessary that they gain approval from the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health. Ensuring FDA approval requires evidence that the device was designed and manufactured under a quality system conforming to US Code of Federal Regulations 21 CFR part 820. Conforming to these standards is not optional – it is illegal to sell medical devices that have not been approved by the FDA. Although the FDA approval process can be tedious, starting with a good quality management system and understanding what the FDA is looking for can help streamline the process and make sure the device ends up getting approved.

Quality Management Standard

Subscribing to a recognized quality management system makes the FDA approval process go much smoother, and helps companies make sure they conform to FDA standards. ISO 13485 is a quality management standard specific to the medical device industry, and is recognized worldwide. Although being ISO 13485 certified does not guarantee approval by the FDA, the standards are so similar that ISO 13485 certified companies are more likely to get their devices approved.

Getting an ISO 13485 certification is a valuable first step in getting approval for the product, and it also helps make sure the device will meet international standards. An ISO 13485 certification demonstrates that a company has a quality management system that complies with the requirements of the FDA, and greatly increases the chances of submitting a complete package to the FDA or international regulatory bodies. It serves as an effective risk management strategy that increases the chances of creating successful products and helps prevent recalls, safety issues, or brand damage.

Submission Guidelines

The first step to successfully getting a device FDA-approved is to understand the FDA submission guidelines. Different types of devices are subject to different types of regulatory policy, so understanding how the FDA classifies devices is important to making sure the product gets approved. The categories are determined by how risky the device is to the user, with riskier products requiring more comprehensive testing.

Class I medical devices, for example elastic bandages or manual stethoscopes, involve little risk to the patient, and only need to be registered with the FDA, rather than approved. Class II medical devices, which include products such as powered wheelchairs or x-ray machines, are more complex and have the potential to pose some risk to the patient, and therefore more information and testing is required to get them certified.

Class II devices require the submission of a 510(k). Class III devices have the potential to pose the most risk to the patient and often play a life-supporting or life-sustaining role, for example pacemakers or breast implants. A device can also be Class III if it is not similar to anything else on the market.

Since Class III devices pose the highest risk, they also require the highest quality assurance, and usually require a premarket approval (PMA). There are some alternative paths to gaining FDA approval, such as using the de novo classification, but generally FDA approval involves either a 510(k) or PMA. Understanding the device’s classification and the information and documentation required by that classification is a key part of getting the FDA to approve the device.

Safety and Efficacy

When reviewing medical devices for approval, the FDA cares primarily about two things: safety and efficacy. Safety is the biggest factor when seeking approval for a medical device, and the more potential risk the device has, the more testing and trials it will have to undergo before it is approved. Risk management is a key part of the process to FDA approval, because obviously a device that is not safe for consumers to use cannot be allowed to go to market. The FDA also requires a design history file (DHF) containing evidence that a compliant quality system was followed to get cleared or approved. Designing medical devices is not just about whether the end design works safely; it’s also about following a compliant process along the way and documenting the process steps as evidence to conformance.

The FDA also wants to determine whether the device is “effective,” essentially whether or not it successfully does what it is supposed to do. The FDA requires documentation demonstrating that the device meets the claims published about the device (in the device “labeling”). The more ambitious the claims about the device, the more extensive the clinical or simulated testing that is required for approval. Ensuring that the device conforms to both safety and efficacy standards helps the device move smoothly through the FDA approval process and get to the point where it can be marketed.

The ‘CE’ Mark

If a company plans to market a device in Europe as well as in the US, a slightly different EU standard must also be met in addition to the standards set out by the FDA. The company must demonstrate that the device meets the requirements in the Medical Device Directive (MDD) by performing a conformity assessment. This assessment varies according to the classification of the device.

This then leads to the device receiving a CE Mark, which is a manufacturer’s declaration that the product complies with the ‘essential requirements’ of the relevant European health, safety, and environmental protection legislation. Although the requirements for receiving FDA approval and a CE mark tend to be very similar, as the CE mark focuses around safety and efficacy as well, they are two different systems and the documentation needs to be submitted separately. Some devices end up with only one or the other.

Conclusion

Seeking FDA approval can be something that is very overwhelming for medical device companies, especially if it a process they have not necessarily gone through before. However, in order to bring a device to market it is absolutely imperative that it goes through the FDA approval process. Although the process is difficult, there are a few things to help make it easier – having a good understanding of how the FDA classification system works can help ensure that companies have completed the right testing and documentation, and focusing on making sure the device is proven to be efficient and safe will go a long way in helping to streamline the process. Additionally, although the CE mark is not the first priority for a company looking to get FDA approval, it is something important to keep in mind to make the process more efficient.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million

Rockwell Medical agreed to acquire most of Vantive's hemodialysis business for $125 million in base consideration, plus up to $45 million in contingent payments, with closing expected mid-2027. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility; the combined business could generate $400-450 million annually, depending on various factors.

  • 01Rockwell Medical acquires Vantive's hemodialysis concentrates, AK 98 machines, water treatment systems, and one-million-square-foot Medolla, Italy manufacturing campus for $125 million base price plus up to $45 million contingent on revenue and EBITDA milestones.
  • 02Combined business targeted to generate $400-450 million in annual revenue depending on operating performance, exchange rates, market conditions and integration.
  • 03Vantive's dialyzer portfolio, including Theranova dialyzer for expanded hemodialysis, remains with Vantive; the company will focus on home dialysis and critical care after divestiture.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512